Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Molson Coors Brewing Company (TAP): Good Product But An Expensive Stock

Valuation

Molson Coors trades for 14.5 times TTM earnings, which are forecast to rise by around 5% annually over the next several years.  I personally think that the stock is a bit overpriced right now, with slow growth and about $1 billion in net debt.  Unless the company provides new growth plans or a rosier outlook for the next several years, I actually think we’ll see a pullback to the lower end of the trading range mentioned earlier.

Anheuser-Busch InBev trades at 19.2 times earnings, however they are growing more aggressively by far.  Consensus estimates call for earnings to rise at a 14.3% average annual rate over the next three years, which more than justifies the higher valuation.

Frequent readers know my “valuation rule” to roughly estimate whether a stock is fairly valued.  Take the forward growth rate and double it.  This number should be more than the P/E multiple, unless the company has a gigantic cash position or other extenuating issues.  Anheuser-Busch Inbev qualifies.  Molson Coors, sadly, does not.

Even the Boston Beer Company looks more attractive as an investment.  The maker of Sam Adams trades at 31 times earnings, with a 15% forward growth rate and has about $50 million in cash and NO debt whatsoever.

Conclusion

As far as Molson Coors goes, my opinion is to basically “wait and see.”  In other words, I need the company to give me a reason to invest in it.  Although I believe they make a quality product, I need them to show me signs of growth comparable to their peers, or at least growth at a level that is on par with the valuation.

The article Good Product But An Expensive Stock originally appeared on Fool.com and is written by Matthew Frankel.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!